Rodman & Renshaw Downgrades Orexigen Therapeutics (OREX) to Underperform
Tweet Send to a FriendGet Alerts OREX Hot Sheet
Price: $6.45 -0.46%
Rating Summary:
6 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
6 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade OREX Now!
Rodman & Renshaw downgraded Orexigen Therapeutics (NASDAQ: OREX) from Market Perform to Market Underperform.
For more ratings news on Orexigen Therapeutics click here and for the rating history of Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $5.47 yesterday, with a 52 week range of $3.81-$8.88.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For more ratings news on Orexigen Therapeutics click here and for the rating history of Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $5.47 yesterday, with a 52 week range of $3.81-$8.88.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- BMO Capital Downgrades Nordson (NDSN) to Market Perform
- Goldman Sachs Downgrades China Mobile (CHL) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Rodman & Renshaw
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
